




PHARMACEUTICAL 2021

Summit Therapeutics Inc.
Rank 164 of 402





PHARMACEUTICAL 2021

Summit Therapeutics Inc.
Rank 164 of 402



The relative strengths and weaknesses of Summit Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Summit Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Summit Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 87% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	87,674
Cost of Goods Sold	0
Intangible Assets	13,545
Liabilities, Current	19,890
Liabilities, Non-Current	3,155
Other Assets	554
Other Compr. Net Income	970
Other Expenses	646
Other Liabilities	0
Other Net Income	283
Other Revenues	20,172
Property and Equipment	725
Research and Development	53,274
Selling, General and Administrative Expense	19,232

Output Variable	Value in 1000 USD
Assets	102,498
Liabilities	23,045
Expenses	73,152
Revenues	20,172
Stockholders Equity	79,453
Net Income	-52,697
Comprehensive Net Income	-52,212
Economic Capital Ratio	135%